Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EP1832Y] to FAK (phospho Y576 + Y577)
- Suitable for: WB, Dot blot
- Reacts with: Mouse
Product nameAnti-FAK (phospho Y576 + Y577) antibody [EP1832Y]
See all FAK primary antibodies
DescriptionRabbit monoclonal [EP1832Y] to FAK (phospho Y576 + Y577)
SpecificityDetects FAK phosphorylated at Y576/577.
Tested Applications & Species
Application Species WBMouse
A phospho specific peptide corresponding to residues surrounding Tyrosine 576/577 of human FAK.
- NIH-3T3 lysate treated with pervanadate.
Rat: We have preliminary internal testing data to indicate this antibody may not react with this species. Please contact us for more information.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles.
Storage bufferpH: 7.20
Preservative: 0.05% Sodium azide
Constituents: 0.1% BSA, 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab76244 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Tested applications are guaranteed to work and covered by our Abpromise guarantee.
Predicted to work for this combination of applications and species but not guaranteed.
Does not work for this combination of applications and species.
1/50000 - 1/100000. Predicted molecular weight: 119 kDa.
1/50000 - 1/100000. Predicted molecular weight: 119 kDa.
FunctionNon-receptor protein-tyrosine kinase implicated in signaling pathways involved in cell motility, proliferation and apoptosis. Activated by tyrosine-phosphorylation in response to either integrin clustering induced by cell adhesion or antibody cross-linking, or via G-protein coupled receptor (GPCR) occupancy by ligands such as bombesin or lysophosphatidic acid, or via LDL receptor occupancy. Microtubule-induced dephosphorylation at Tyr-397 is crucial for the induction of focal adhesion disassembly. Plays a potential role in oncogenic transformations resulting in increased kinase activity.
Tissue specificityExpressed in all organs tested, in lymphoid cell lines, but most abundantly in brain.
Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. FAK subfamily.
Contains 1 FERM domain.
Contains 1 protein kinase domain.
DomainThe first Pro-rich domain interacts with the SH3 domain of CRK-associated substrate (BCAR1) and CASL.
The carboxy-terminal region is the site of focal adhesion targeting (FAT) sequence which mediates the localization of FAK1 to focal adhesions.
modificationsPhosphorylated on 6 tyrosine residues upon activation. Microtubule-induced dephosphorylation at Tyr-397 could be catalyzed by PTPN11 and regulated by ZFYVE21. Dephosphorylated by PTPN11 upon EPHA2 activation by its ligand EFNA1.
Cellular localizationCell junction > focal adhesion. Cell membrane. Constituent of focal adhesions.
- Information by UniProt
- FADK 1 antibody
- FADK antibody
- FAK related non kinase polypeptide antibody
Anti-FAK (phospho Y576 + Y577) antibody [EP1832Y] (ab76244) Dot Blot. Primary ab dilution 1:1000, Secondary ab description and code (ab id), Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051), Secondary ab dilution 1:100,000, Blocking buffer and concentration 5% NFDM/TBST, Diluting buffer and concentration 5% NFDM /TBST, Lane 1:FAK (pY576+pY577) phospho peptide, Lane 2:FAK (pY576) phospho peptide, Lane 3:FAK (pY577) phospho peptide, Lane 4:FAK non-phospho peptide, Exposure time 3 minutes. Note: antibody used for ab76244 is purified batch.
All lanes : Anti-FAK (phospho Y576 + Y577) antibody [EP1832Y] (ab76244) at 1/50000 dilution
Lane 1 : NIH-3T3 cell lysates, untreated
Lane 2 : NIH-3T3 cell lysates treated with pervanadate
Lysates/proteins at 10 µg per lane.
All lanes : HRP labelled goat anti-rabbit at 1/1000 dilution
Predicted band size: 119 kDa
Observed band size: 125 kDa why is the actual band size different from the predicted?
ab76244 has been referenced in 9 publications.
- Cho HJ et al. Identification of SYK inhibitor, R406 as a novel senolytic agent. Aging (Albany NY) 12:8221-8240 (2020). PubMed: 32379705
- Husari A et al. On the relationship of YAP and FAK in hMSCs and osteosarcoma cells: Discrimination of FAK modulation by nuclear YAP depletion or YAP silencing. Cell Signal 63:109382 (2019). PubMed: 31376525
- Qiu W et al. Hypoxia-induced EPHB2 promotes invasive potential of glioblastoma. Int J Clin Exp Pathol 12:539-548 (2019). PubMed: 31933858
- Phanthaphol N et al. Upregulation of TCTP is associated with cholangiocarcinoma progression and metastasis. Oncol Lett 14:5973-5979 (2017). PubMed: 29113234
- Bernusso VA et al. Imatinib restores VASP activity and its interaction with Zyxin in BCR-ABL leukemic cells. Biochim Biophys Acta 1853:388-95 (2015). PubMed: 25450971
- Goodwin JM et al. An AMPK-independent signaling pathway downstream of the LKB1 tumor suppressor controls Snail1 and metastatic potential. Mol Cell 55:436-50 (2014). PubMed: 25042806
- Huang H et al. Niacin reverses migratory macrophage foam cell arrest mediated by oxLDL in vitro. PLoS One 9:e114643 (2014). PubMed: 25521578
- Huang H et al. Induction of inducible nitric oxide synthase (iNOS) expression by oxLDL inhibits macrophage derived foam cell migration. Atherosclerosis 235:213-22 (2014). PubMed: 24858340
- Ratke J et al. Leptin stimulates the migration of colon carcinoma cells by multiple signaling pathways. Endocr Relat Cancer 17:179-89 (2010). PubMed: 19952122